RxDoctor Payments Data

William Watkins, MD

Internal Medicine · Denison, TXNPI 1679527527

Payments from drug & device makers

$319in general payments, 2019–2025

Across 20 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$92
  • Amgen$47
  • Novo Nordisk$44
  • Novartis$31
  • GSK$29
  • Otsuka America Pharmaceutical, Inc.$21
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$319100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$319 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$298,575
Medicare patients
448
Services billed
15,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide193$212,958
OzempicSemaglutide124$146,861
EliquisApixaban156$140,812
JardianceEmpagliflozin112$98,861
FarxigaDapagliflozin Propanediol67$65,214
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$41,594
JanuviaSitagliptin Phosphate33$38,688
XareltoRivaroxaban32$36,210
KerendiaFinerenone38$32,156
RybelsusSemaglutide29$28,858
EntrestoSacubitril/Valsartan24$25,860
MyrbetriqMirabegron48$23,938
LinzessLinaclotide21$21,341
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$16,435
Breo ElliptaFluticasone/Vilanterol14$9,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$15$212,958193 claims
Novo NordiskOzempic, Rybelsus$44$175,718153 claims
PfizerEliquis$92$140,812156 claims
Boehringer IngelheimJardiance$13$98,861112 claims
AstraZenecaFarxiga, Breztri Aerosphere$12$81,64983 claims
GSKTrelegy Ellipta, Breo Ellipta$29$50,76159 claims
NovartisEntresto$31$25,86024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Denison

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →